Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Equity Ratio (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Equity Ratio for 11 consecutive years, with 0.84 as the latest value for Q3 2025.

  • On a quarterly basis, Equity Ratio rose 1117.1% to 0.84 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.84, a 1117.1% increase, with the full-year FY2023 number at 0.85, up 2.31% from a year prior.
  • Equity Ratio was 0.84 for Q3 2025 at Crescent Biopharma, down from 0.88 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.91 in Q1 2021 to a low of 5.03 in Q1 2025.
  • A 5-year average of 0.49 and a median of 0.86 in 2022 define the central range for Equity Ratio.
  • Biggest YoY gain for Equity Ratio was 1117.1% in 2025; the steepest drop was 695.51% in 2025.
  • Crescent Biopharma's Equity Ratio stood at 0.86 in 2021, then decreased by 4.2% to 0.83 in 2022, then rose by 2.31% to 0.85 in 2023, then tumbled by 109.78% to 0.08 in 2024, then skyrocketed by 1117.1% to 0.84 in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Equity Ratio are 0.84 (Q3 2025), 0.88 (Q2 2025), and 5.03 (Q1 2025).